Actavis launches three new generic products in Europe

By Elaine Rigoli

Tampa, Fla., May 30 - Actavis Group said Tuesday that it has launched three new generic products into a number of key European markets including Germany, the United Kingdom, Hungary and Poland.

The drugs include Sumatriptan, used to treat migraine headaches, the atypical antipsychotic Risperidone and Granisetron, the anti-nausea drug.

The new drugs have been developed in Actavis' in-house research and development facilities in Iceland and Malta and by Actavis' partners in India, according to a news release.

Based in Reykjavik, Iceland, Actavis is an international generic pharmaceuticals company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.